NEW YORK, November 3, 2017 - Omnicom Health Group, part of Omnicom (NYSE: OMC), announced today that Kirsten A. Kantak has been appointed CEO of Biolumina, reporting to Ed Wise, CEO of Omnicom Health Group. She succeeds Ty Curran, who has been promoted to chairman.
Most recently, Kantak served as president of Biolumina. She was promoted to president in 2015. Prior to Biolumina, Kantak was at Harrison and Star for 13 years, most recently as senior vice president, global managing director.
'Kirsten helped take Biolumina into the future, cementing it as a fierce competitor in the healthcare space,' said Curran. 'She accomplished this through tremendous new business growth as well as a significant focus on culture. I have no doubt the agency will continue to thrive under Kirsten's strong leadership.'
'Kirsten's talent-first approach and passion for delivering superior work for clients will take Biolumina to the next stage in its evolution,' said Wise. 'I look forward to continuing to watch the agency's upward trajectory.'
In his role as chairman, Curran will serve in a consultative role to Kantak, and will take on special healthcare projects across Omnicom Health Group. He will report to Dale Adams, chairman and CEO, the DAS Group of Companies. Prior to this role, Curran served as CEO of Biolumina, as well as sister agency Harrison and Star.
'Ty's leadership took Biolumina on a strong growth path, and he will continue to provide valuable strategic counsel and guidance in his role as chairman,' said Adams.
The changes are effective January 1, 2018.